Offerings (SEC Form D)
Each filing as reported by the issuer, newest first. Open a row for the full plain-English detail. D = original notice, D/A = amendment.
Offerings at a glance — 5 offerings, 5 filings (one row per SEC file number)
| File no. | Original Form D | Latest filing | Amendments | Offered (latest) | Sold (latest) | Industry (latest) |
|---|
| 021-510464 | Apr 12, 2024 EDGAR ↗ | Apr 12, 2024 D EDGAR ↗ | 0 | $23,500,000 | $350,000 | Biotechnology |
| 021-478197 | Apr 7, 2023 EDGAR ↗ | Apr 7, 2023 D EDGAR ↗ | 0 | $5,000,000 | $684,651 | Biotechnology |
| 021-426873 | Dec 28, 2021 EDGAR ↗ | Dec 28, 2021 D EDGAR ↗ | 0 | $7,000,000 | $1,135,000 | Biotechnology |
| 021-393628 | Mar 26, 2021 EDGAR ↗ | Mar 26, 2021 D EDGAR ↗ | 0 | $10,000,000 | $2,899,500 | Other Technology |
| 021-351657 | Oct 23, 2019 EDGAR ↗ | Oct 23, 2019 D EDGAR ↗ | 0 | $6,000,000 | $2,087,980 | Other Technology |
Offerings are grouped by SEC file number; rows without a file number (not yet retrieved from EDGAR) are shown as their own offering until the link is fetched.
Apr 12, 2024 D Biotechnology — $350,000 sold of $23,500,000 · 2 investors EDGAR ↗
| Filing | Form D filed Apr 12, 2024SEC file no. 021-510464 · accession 0001493152-24-014408 |
|---|
| Raise progress | $350,000 sold of $23,500,000 offered (1%) · $23,150,000 remaining · first sale Apr 9, 2024 |
|---|
| Filing timing | Date of first sale: Apr 9, 2024 · Form D filed: Apr 12, 2024 (3 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 928 days (2.5 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 2 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity; Debt; Option, warrant or other right to acquire |
|---|
| Entity details | Organized in DELAWARE · formed 2019 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | Laidlaw & Company (UK) Ltd. — FINRA BrokerCheck CRD 000119037 ↗ Solicits in: All States |
|---|
| Money to insiders | Sales commissions: $420,000 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $210,000 Issuer's note: Assumes maximum commission fees paid. · Issuer's note: The Company will use $210,000 to repay a non-interest bearing loan issued by an affiliate of the Company. |
|---|
| Signed by | David Cavalier, Chief Financial Officer (Apr 12, 2024) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $23,500,000. Typical range: $2,000,000–$19,999,994.
Investors: 2. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Apr 7, 2023 D Biotechnology — $684,651 sold of $5,000,000 · 35 investors EDGAR ↗
| Filing | Form D filed Apr 7, 2023SEC file no. 021-478197 · accession 0001493152-23-011301 |
|---|
| Raise progress | $684,651 sold of $5,000,000 offered (14%) · $4,315,349 remaining · first sale May 3, 2022 |
|---|
| Filing timing | Date of first sale: May 3, 2022 · Form D filed: Apr 7, 2023 (339 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 1,635 days (4.5 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 35 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $50,000 |
|---|
| Securities offered | Equity; Other: Series C Preferred Stock |
|---|
| Entity details | Organized in DELAWARE · formed 2019 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 (est.) |
|---|
| Signed by | David Cavalier, Chief Financial Officer (Apr 6, 2023) |
|---|
| Market context | Minimum investment: $50,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $5,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 35. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Dec 28, 2021 D Biotechnology — $1,135,000 sold of $7,000,000 · 10 investors EDGAR ↗
| Filing | Form D filed Dec 28, 2021SEC file no. 021-426873 · accession 0001493152-21-032552 |
|---|
| Raise progress | $1,135,000 sold of $7,000,000 offered (16%) · $5,865,000 remaining · first sale Dec 13, 2021 |
|---|
| Filing timing | Date of first sale: Dec 13, 2021 · Form D filed: Dec 28, 2021 (15 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 1,776 days (4.9 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 10 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $25,000 |
|---|
| Securities offered | Equity; Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed 2019 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | Laidlaw & Company (UK) Ltd. — FINRA BrokerCheck CRD 119037 ↗ Solicits in: All States |
|---|
| Money to insiders | Sales commissions: $560,000 (est.) · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 (est.) Issuer's note: Assumes maximum commissions earned on the maximum potential offering amount of $7,000,000. As of the date of filing this Form D, the Company has received investments totalling $1,135,000, and Laidlaw has earned commissions of $90,800. · Issuer's note: Some of the proceeds of the offering may be used for general working capital purposes which may include the payment of salaries and other fees to those individuals listed in Item 3. To date, no offering proceeds have been used for such purposes. |
|---|
| Signed by | David Cavalier, Chief Financial Officer (Dec 27, 2021) |
|---|
| Market context | Minimum investment: $25,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $7,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 10. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Mar 26, 2021 D Other Technology — $2,899,500 sold of $10,000,000 · 39 investors EDGAR ↗
| Filing | Form D filed Mar 26, 2021SEC file no. 021-393628 · accession 0000905718-21-000445 |
|---|
| Raise progress | $2,899,500 sold of $10,000,000 offered (29%) · $7,100,500 remaining · first sale Mar 12, 2021 |
|---|
| Filing timing | Date of first sale: Mar 12, 2021 · Form D filed: Mar 26, 2021 (14 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 2,052 days (5.6 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 39 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity; Other: Series B Preferred Stock |
|---|
| Entity details | Organized in DELAWARE · formed 2019 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Other Technology |
|---|
| Who is paid to sell it | Laidlaw & Company (UK) Ltd. — FINRA BrokerCheck CRD 119037 ↗ Solicits in: All States |
|---|
| Money to insiders | Sales commissions: $1,200,000 (est.) · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 (est.) Issuer's note: Assumes maximum commissions earned, includes non-accountable expense fee. · Issuer's note: Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3. |
|---|
| Signed by | Matthew Duffy, Chief Executive Officer (Mar 26, 2021) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $5,000–$50,000.
Offering size: $10,000,000. Typical range: $1,100,015–$10,001,163.
Investors: 39. Typical range: 2–14."Similar" = Other Technology, Rule 506(b). Based on 17,390 Form D filings 2021–2026 in the same industry and exemption (Other Technology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 4,892, offering size 16,373, investors 16,629. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Oct 23, 2019 D Other Technology — $2,087,980 sold of $6,000,000 · 23 investors EDGAR ↗
| Filing | Form D filed Oct 23, 2019SEC file no. 021-351657 · accession 0000905718-19-000867 |
|---|
| Raise progress | $2,087,980 sold of $6,000,000 offered (35%) · $3,912,020 remaining · first sale Oct 10, 2019 |
|---|
| Filing timing | Date of first sale: Oct 10, 2019 · Form D filed: Oct 23, 2019 (13 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 2,571 days (7.0 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 23 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed 2019 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Other Technology |
|---|
| Who is paid to sell it | Laidlaw & Company (UK) Ltd. — FINRA BrokerCheck CRD 119037 ↗ Solicits in: All States |
|---|
| Money to insiders | Sales commissions: $770,000 (est.) · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 (est.) Issuer's note: Assumes maximum commissions earned, excludes value of warrants to purchase common stock earned as part of commission. · Issuer's note: Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3. |
|---|
| Signed by | Matthew Duffy, Chief Executive Officer (Oct 23, 2019) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $5,000–$50,000.
Offering size: $6,000,000. Typical range: $1,100,015–$10,001,163.
Investors: 23. Typical range: 2–14."Similar" = Other Technology, Rule 506(b). Based on 17,390 Form D filings 2021–2026 in the same industry and exemption (Other Technology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 4,892, offering size 16,373, investors 16,629. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
All Form D filings for this CIK on SEC EDGAR ↗. History: 0 new offerings in the last 12 months (new offering = a Form D that is not an amendment) · most recent filing Apr 12, 2024. Industry as reported, by offering: Previous offerings: Other Technology (2019–2021). Latest offering: Biotechnology (2021–2024; most recent Apr 12, 2024).
Key people 12
Officers, directors and promoters the issuer itself named on its Form D. Tap a name for every other deal they are on.
| Name | Relationship | Address state | On filings (first → last) | Also listed on |
|---|
| AZ Anthony Zook | Director | NY | Dec 28, 2021 → Apr 12, 2024 on 3 of 5 filings listed on the latest filing | 4 other issuers |
| DC David Cavalier | Executive Officer Issuer's note: Chief Financial Officer and Chief Operating Officer | NY | Dec 28, 2021 → Apr 12, 2024 on 3 of 5 filings listed on the latest filing | — |
| GG Gary Gemignani | Director | NY | Apr 7, 2023 → Apr 12, 2024 on 2 of 5 filings listed on the latest filing | 1 other issuer |
| JA James Ahern | Director | NY | Oct 23, 2019 → Apr 12, 2024 on 5 of 5 filings listed on the latest filing | 4 other issuers |
| JD Jeffrey O'Donnell | Director | NY | Dec 28, 2021 → Apr 12, 2024 on 3 of 5 filings listed on the latest filing | 13 other issuers |
| KM Kamal Mubark | Director | NY | Apr 7, 2023 → Apr 12, 2024 on 2 of 5 filings listed on the latest filing | — |
| MD Matthew Duffy | Executive Officer, Director Issuer's note: Executive Chairman, Secretary | NY | Oct 23, 2019 → Apr 12, 2024 on 4 of 5 filings listed on the latest filing | 3 other issuers |
| MT Michael Tilton | Executive Officer, Director Issuer's note: Chief Executive Officer | NY | Dec 28, 2021 → Apr 12, 2024 on 3 of 5 filings listed on the latest filing | — |
| PG Patrick Gallagher | Director | NY | Oct 23, 2019 → Apr 12, 2024 on 5 of 5 filings listed on the latest filing | 12 other issuers |
| GG Gary Gemigani | Director | NY | Dec 28, 2021 on 1 of 5 filings not listed on the latest filing (Apr 12, 2024) | — |
| KM Kamal Mubarak | Executive Officer, Director Issuer's note: President, Chief Scientific Officer | NY | Oct 23, 2019 → Dec 28, 2021 on 3 of 5 filings not listed on the latest filing (Apr 12, 2024) | — |
| JD Jeff O'Donnell | Director | NY | Mar 26, 2021 on 1 of 5 filings not listed on the latest filing (Apr 12, 2024) | — |
Executive officers, directors and promoters as self-reported by the issuer, one row per person. Spellings of the same name (same first and last name, or the same full name that EDGAR split differently into middle and last name) with no conflicting middle initial are shown on one row (none on this issuer); dates and counts come from the filings that list each name. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.
Connections
Other issuers listing the same people:
- Lucius Partners Opportunity Fund, LP — James Ahern · latest filing Oct 9, 2026
- ADAPTIN BIO, INC. — Patrick Gallagher · latest filing Jun 22, 2026
- ADAPTIN BIO, INC. — Anthony Zook · latest filing Jun 22, 2026
- Waypoint Orthopedics, Inc. — Jeffrey O'Donnell · latest filing Mar 19, 2026
- Pace Surgical, Inc. — Jeffrey O'Donnell · latest filing Feb 17, 2026
- Accure Acne, Inc. — Jeffrey O'Donnell · latest filing Nov 25, 2025
- Micro Interventional Devices, Inc. — Jeffrey O'Donnell · latest filing Sep 18, 2025
- BioSig Technologies, Inc. — Patrick Gallagher · latest filing Mar 26, 2025
- BioSig Technologies, Inc. — Anthony Zook · latest filing Mar 26, 2025
- BioSig Technologies, Inc. — Jeffrey O'Donnell · latest filing Mar 26, 2025
- Runway Healthcare Fund II, L.P. — Jeffrey O'Donnell · latest filing Jan 30, 2025
- PD Theranostics, Inc. — James Ahern · latest filing Dec 14, 2023
- PD Theranostics, Inc. — Patrick Gallagher · latest filing Dec 14, 2023
- PD Theranostics, Inc. — Matthew Duffy · latest filing Dec 14, 2023
- Voltron Therapeutics, Inc. — James Ahern · latest filing Nov 9, 2023
- Voltron Therapeutics, Inc. — Patrick Gallagher · latest filing Nov 9, 2023
- Voltron Therapeutics, Inc. — Matthew Duffy · latest filing Nov 9, 2023
- Voltron Therapeutics, Inc. — Anthony Zook · latest filing Nov 9, 2023
- Aerwave Medical, Inc. — James Ahern · latest filing Aug 17, 2023
- Aerwave Medical, Inc. — Patrick Gallagher · latest filing Aug 17, 2023
- Aerwave Medical, Inc. — Matthew Duffy · latest filing Aug 17, 2023
- Aerwave Medical, Inc. — Jeffrey O'Donnell · latest filing Aug 17, 2023
- Trice Medical, Inc. — Jeffrey O'Donnell · latest filing Aug 4, 2023
- Watt Fuel Cell Corp. — Patrick Gallagher · latest filing Dec 7, 2022
- Tuesday Capital V, L.P. — Patrick Gallagher · latest filing May 31, 2022
- Tuesday Capital IV, L.P. — Patrick Gallagher · latest filing Mar 31, 2021
- Runway Healthcare, LP — Jeffrey O'Donnell · latest filing Dec 1, 2020
- ViralClear Pharmaceuticals, Inc. — Anthony Zook · latest filing Jun 3, 2020
- ViralClear Pharmaceuticals, Inc. — Jeffrey O'Donnell · latest filing Jun 3, 2020
- Fortress Biotech, Inc. — Gary Gemignani · latest filing Mar 13, 2018
- Crunch Fund III, L.P. — Patrick Gallagher · latest filing Apr 20, 2016
- BioStar Ventures III, L.P. — Jeffrey O'Donnell · latest filing Sep 16, 2015
- YouMail, Inc. — Patrick Gallagher · latest filing Feb 9, 2015
- Crunch Fund II, L.P. — Patrick Gallagher · latest filing Jan 30, 2014
- Nitric BioTherapeutics, Inc. — Jeffrey O'Donnell · latest filing Jan 20, 2012
- Crunch Fund I, L.P. — Patrick Gallagher · latest filing Sep 14, 2011
- Embrella Cardiovascular Inc — Jeffrey O'Donnell · latest filing Aug 25, 2009
Shared address: this business address appears on filings for 3 other issuers. Stated as a count only (suite numbers ignored) — many addresses are shared office buildings or registered agents. As of Oct 23, 2026, 5:45 PM ET.
Address of record is shared by 7 issuers in SEC Form D filings (shared office, PartnerFacts count as of Oct 23, 2026, 5:45 PM ET) — not used to group this issuer.
Other offering types (Regulation A and Regulation Crowdfunding)
Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.
Adviser registration (Form ADV)
Searched SEC Form ADV bulk data (registered + exempt reporting advisers) (24,962 records as of Oct 2, 2026, 8:00 AM ET) — nothing matched Algorithm Sciences, Inc..
Meta advertising
No Meta Pixel ids or Facebook / Instagram page links on file for Algorithm Sciences, Inc. as of Oct 24, 2026 — the sponsor website is read for them once it is on file (runs automatically). Meta Ad Library: not searched by PartnerFacts (no API access); a one-tap Ad Library search is under Look further.
Public profiles
Public profiles official links and public statements, each with its source and date
No website or social profile named in Algorithm Sciences, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #102,528 of 374,652 in line (14 issuers searched so far).
Sources searched for a website: Form C data set (issuer websites as filed), Form ADV data set (Item 1.I of matched advisers) — as of Oct 23, 2026, 11:20 PM ET: none on file for this issuer. The sponsor website, the Internet Archive and GDELT news index are read only once a site is on file; a sponsor's website comes from the issuer's own filings (Form C issuer website; EDGAR company profile), an approved profile claim, Form ADV Item 1.I of its matched adviser, or a web search for the issuer name confirmed on the site's own homepage. We never collect personal or family accounts.
Entity standing: not checked (no official programmatic source for NY yet).
Export this report as PDF (all source links + data timestamp) · Premium
Request diligence pack (Premium) PartnerFacts asks the sponsor for the standard information pack and delivers it to you labelled "provided by the sponsor".
Corrections log
No corrections have been requested for this page.
Filing-to-filing changes are in Amendment history above.
Email me the full report
The complete public-record profile for Algorithm Sciences, Inc., plus the weekly new-filings list.
What do you want to do?
Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.
Request a correction
Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).
Sponsor response
Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.
Claim this profile (sponsors)
Free. Get the "Claimed by sponsor" chip and a confirmed contact for corrections. Claiming never changes the public-record section.